web maker

Chemotherapy, the term that identified the first systemic therapy for cancer was well chosen by founder Ezra Greenspan in 1968 to name this not-for-profit organization as The Chemotherapy Foundation. With the goal and purpose of incubating more curative therapies, the Foundation continues to serve as a launching pad for emerging developments in cancer medicine.

The Chemotherapy Foundation
Supporting Innovative Research for
Continuing Progress in the Control
and Cure of Cancer

36th Annual CFS November 7-9, 2018
Chemotherapy Foundation Symposium

Innovative Cancer Therapy for Tomorrow
Marriot Marquis, NYC
The Greenspan Meeting Founded in 1972

Empowering Ongoing Progress

[Upcoming Events]

Innovation Gala
Wednesday, November 7, 2018
Cocktails, Dinner, Awards Program
6:00 to 9:00 PM
Russian Tea Room
150 West 57th Street
New York City
Business Attire

Guest of Honor Pierce Brosnan
In Recognition of his Support for Research
Advancing Control and Cure of Women's Cancers

Event Information

Building the Bridge between the
Laboratory Bench and Oncology Practice

(See Research Achievements of The Chemotherapy Foundation)


Your Contribution is an
Investment in Continuing Progress

Half a century ago, when oncology was a newly recognized
specialty of medicine, Ezra Greenspan opened a window to the future.
He broke new ground in treating cancer patients with
combinations of active agents, leading the way to targeted
therapies, biologics, Immunotherapy and the
potent promises of gene therapy.




The Foundation Research Grant Program is providing startup seed money for the innovative investigators spearheading advances in cancer theraputics.



Michael G. Rosenberg, Founder, President and CEO, The Promotion In Motion Companies, Inc. named President and CEO of The Chemotherapy Foundation. Mr. Rosenberg brings his entrepreneurial energies to advocacy of the innovative Cancer Research Program supported by the Foundation. Heading up a global operation, Promotion in Motion, one of the largest snack and confectionary companies ln the world he met the demand for healthier refreshment options in creating Welch's Real Fruit Snacks. Michael Rosenberg welcomes the opportunity to employ his leadership skills in growing the support strata of the Foundation.

William K. Oh, MD, a recognized specialist in the management of genitourinary malignancies including prostate, renal, bladder and testicular cancers, Chief of Hematology and Medical Oncology, Deputy Director,and Associate Director for Clinical Research, Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, Trustee of The Chemotherapy Foundation and Ezra M. Greenspan Professor of Clinical Medicine he carries on a pioneering legacy. The Tisch Cancer Institute received the prestigious NCI-designation in 2015. Dr. Oh’s research interests include novel biomarkers and therapeutics in advanced prostate cancer. He served as the principal investigator of multiple clinical trials in prostate and other GU cancers.

Ezra Greenspan, MD

1919 - 2004
Founder of The Chemotherapy Foundation, Clinical Professor of Medicine, Mount Sinai School of Medicine

Dr. Greenspan was a pioneering oncologist who founded The Chemotherapy Foundation in 1968 and its professional education arm, The Chemotherapy Foundation Symposium in 1972, to bring the new developments in cancer therapeutics to practicing oncologists in the years ahead. His goal was the control and eventual cure of cancer. His early work is widely recognized as a forerunner to current progress in combating many types of cancer.

Franco M. Muggia, MD

Chairman and Medical Director of The Chemotheraphy Foundation. Professor, Department of Medicine at The NYU Langone Medical Center

Dr. Muggia is a widely recognized expert and thought leader in clinical oncology. In collaboration with the Associate Medical Directors and the Scientific Advisory Council he is responsible for selection of the research projects and investigators funded by The Chemotherapy Foundation. He has published widely and lectured extensively in his specialty of gynecological cancers. During the years he headed the Cancer Therapy Evaluation Program at the National Cancer Institute he collaborated with Bonadonna, Fisher, Wolmark and other early leaders. With Ezra Greenspan he introduced the first Chemoprevention drug Tamoxifen. As leader of the Gynecologic Oncology Group he chaired the Medical Oncology Committee of the Gynecologic Oncology Group.

Michael G. Rosenberg

President and CEO of The
Chemotherapy Foundation
Founder, President and CEO
The Promotion in Motion Companies, Inc.

Mr. Rosenberg brings his entrepreneurial energies to advocacy of the cancer research supported by the Foundation. While an undergraduate at American University he launched an innovative marketing company, a fledging enterprise that developed into a powerhouse global operation in the confectionery and snack foods industry under his creative leadership. To meet the rapidly increasing demand for healthier snacks, he turned to food science experts in order to bring many varieties of real fruit snacks to the worldwide consumer markets. He currently serves as Chairman of the Washington, DC based National Confectioners Association (one of the oldest trade associations in the nation) and as a key participant in the Partnership For A Healthier America. Michael Rosenberg believes that the business community should contribute to the betterment of health and wellbeing of the public and brings equal zeal to his new role as President of The Chemotherapy Foundation a not-for-profit organization providing start-up grants to investigators seeking curative therapies for cancer. He believes corporate good citizenship requires investment of resources in such activities. Mr. Rosenberg replaces the late Barry Richter as Foundation President and CEO.

Edward P.  Ambinder, MD

Director of Digital Medicine
Clinical Professor of Medicine Emeritus, Hematology and Medical Oncology, Tisch Cancer Institute at the Icahn School of Medicine, Mount Sinai

Dr. Ambinder, a recognized leader in oncology education, practice management and informatics, is responsible for new educational and informatic initiatives of the Foundation. Dr. Ambinder serves on the Grant Review Committee of the Foundation.

The Chemotherapy Foundation is a 501(c)(3) not-for-profit charitable, educational,

scientific organization and your gift is tax deductible to the extent allowable by law.